Valstar (Valrubicin)
| VALSTAR� (valrubicin) is indicated for intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Click the link below to learn more about Valstar – (Valrubicin) |
Urologic Oncology
Education / Resources
- American Cancer Society
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- National Comprehensive Cancer Network (NCCN)
Prostate Cancer Therapeutics
- Xtandi – Enzalutamide
- Vantas – Histrelin Acetate
- LupronDepot – Leuprolide Acetate for Depot Suspension
- Eligard – Leuprolide Acetate for Injectable Suspension
- Firmagon – Degarelix for Injection
- Xgeva – Denosumab Injection
- Prolia – Denosumab
- Zytiga – Abiratirone
Bladder Cancer Therapeutics
Technologies
